Cat. No. 1398
Chemical Name: 9-Bromo-7,12-dihydro-indolo[3,2-d][
Biological ActivityPotent inhibitor of CDK1/cyclin B and GSK-3β (IC50 values are 0.4 and 0.23 μM respectively). Also inhibits CDK2/cyclin A, CDK2/cyclin E and CDK5/cyclin/p35 (IC50 values are 0.68, 7.5 and 0.85 μM respectively). Selective over c-src (IC50 = 15 μM), casein kinase 2 (IC50 = 20 μM), ERK1 (IC50 = 20 μM), ERK2 (IC50 = 9 μM) and a range of other protein kinases (IC50 values > 35 μM). Generates induced pluripotent stem cells (iPSCs) from somatic cells when used in combination with reprogramming factors; can replace Klf4.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Schultz et al (1999) Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J.Med.Chem. 42 2909. PMID: 10425100.
Zaharevitz et al (1999) Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases. Cancer Res. 59 2566. PMID: 10363974.
Buolamwini (2000) Cell cycle targets in novel anticancer drug discovery. Curr.Pharm.Des. 6 379. PMID: 10788588.
Lyssiotis et al (2009) Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. Proc.Natl.Acad.Sci.U.S.A. 106 8912. PMID: 19447925 .
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Kenpaullone, supplier, GSK-3β, GSK-3beta, inhibitors, cdks, Potent, cyclin-dependent, kinase, GSK, Glycogen, Synthase, Kinase, 3, beta, Kinases, Cdk, Cyclin-Dependent, Protein, Carbohydrate, Metabolism, CDK1/cyclin, B, CDK2/cyclin, A, E, CDK5/cyclin/p35, stem, cells
Find multiple products by catalog number
New Products in this Area
Selective PFKFB3 inhibitorPD 0332991 isethionate
Potent, selective Cdk4/6 inhibitor; brain penetrantXL 413 hydrochloride
Potent and selective Cdc7 inhibitorC16
PKR inhibitorRp-8-pCPT-cGMPS sodium
PKG inhibitorTC-S 7004
Potent and selective DYRK1A/B inhibitorTAK 960 hydrochloride
Potent and selective PLK1 inhibitorA12B4C3
Potent and selective polynucleotide kinase/phosphatase (PKNP) inhibitorBMS 345541
Selective allosteric inhibitor of IKK; anti-inflammatoryWH-4-023
Potent and selective Lck and Src inhibitor; also inhibits SIKTC-S 7006
Potent and selective Tpl2 (Cot; MAP3K8) inhibitorOXA 06 dihydrochloride
Potent ROCK inhibitorPCI 29732
Potent BTK inhibitorMps1-IN-1 dihydrochloride
Selective monopolar spindle 1 (Mps1) kinase inhibitorCKI 7 dihydrochloride
CK1 inhibitorT 5601640
Selective LIMK2 inhibitor; antitumor3PO
PFKFB3 inhibitor; antiangiogenicCHR 6494 trifluoroacetate
Potent and selective haspin kinase inhibitorUNC 3230
Potent and selective PIP5K1C inhibitor; antinociceptivetrans-ISRIB
Integrated stress response (ISR) inhibitorBMS 509744
Potent and selective ITK inhibitor
July 7 - 11, 2015
Rio de Janeiro, Brazil